Skip to main content
For Healthcare Professionals
Banner-Background

OVERALL POPULATION

JASCAYD® demonstrated a statistically significant reduction in FVC decline1,2,*,†

IPF-FVC-Decline-COMBINATION-18 mg
IPF-FVC-Decline-COMBINATION-18 mg
JASCAYD® demonstrated a statistically significant reduction in FVC decline 9 mg
JASCAYD® demonstrated a statistically significant reduction in FVC decline 9 mg

*Statistical significance applies to the primary endpoint at week 52 only. Analyses beyond week 52 are exploratory.1

†Concomitant use of JASCAYD® with pirfenidone decreased JASCAYD® exposure by approximately 50%. Therefore, no relative reduction in FVC decline was observed in patients taking JASCAYD® 9 mg vs placebo with pirfenidone.3

JASCAYD® is a disease-modifying therapy proven to slow the decline of lung function in IPF4,5

AF, antifibrotic; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis.

JASCAYD® 18 mg demonstrated an early and sustained reduction in lung function decline that continued to diverge over 76 weeks2

JASCAYD® 18 mg demonstrated an early and sustained reduction continued to diverge over 76 weeks
JASCAYD® 18 mg demonstrated an early and sustained reduction continued to diverge over 76 weeks
Quicklinks

MONOTHERAPY

JASCAYD® 18 mg as monotherapy demonstrated a reduction in FVC decline2

These results were consistent with the overall population2

JASCAYD® 18 mg as monotherapy demonstrated a reduction in FVC decline
JASCAYD® 18 mg as monotherapy demonstrated a reduction in FVC decline

COMBINATION

JASCAYD® 18 mg demonstrated consistent results across all patient subgroups2,†

These results were consistent with the overall population2

IPF-FVC-Decline-SUMMARY-18-mg
IPF-FVC-Decline-SUMMARY-18-mg

*Statistical significance applies to the primary endpoint at week 52 only. Analyses beyond week 52 are exploratory.1

†Concomitant use of JASCAYD® with pirfenidone decreased JASCAYD® exposure by approximately 50%. Therefore, no relative reduction in FVC decline was observed in patients taking JASCAYD® 9 mg vs placebo with pirfenidone.3

JASCAYD® was proven to preserve lung function by reducing FVC decline1,2

Quicklinks

References

  1. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2025;392(22):2193-2202.

  2. Oldham JM, Azuma A, Kreuter M, et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial. Am J Respir Crit Care Med. 2026;212(5):972-980.

  3. JASCAYD® UAE Local SmPC; May 2026.

  4. Reininger D, Wolf F, Mayr CH, et al. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol. 2025;73(5):700-712.

  5. Herrmann FE, Hesslinger C, Wollin L, Nickolaus P. BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis. Front Pharmacol. 2022;13:838449.

MLR ID: PC-AE-102892
Expiry Date: 10/05/2028